Hypha Discovery
Hypha Discovery is a UK-based specialist CRO that produces drug and pesticide metabolites and derivatives for global pharmaceutical and agrochemical companies, combining proprietary enzyme screening kits with biotransformation and NMR-based structure elucidation services.
- Company typePrivate
- Founded2004
- HeadquartersAbingdon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Hypha Discovery does
Hypha Discovery is a UK-based specialist Contract Research Organization (CRO) that provides metabolite synthesis, purification, and metabolite identification (MetID) services to the global pharmaceutical and agrochemical industries. Founded in 2004 and headquartered in Slough with 11-50 employees, the firm generates revenue through a mix of project-based professional services (MetID, metabolite synthesis, purification with Certificates of Analysis, contract fermentation, custom natural product synthesis) and catalog sales of proprietary screening kits (PolyCYPs®+, PolyUGTs) and recombinant enzymes (Human AOX1, Human FMOs). Named enterprise customers include Incyte, Alkermes, and Crestone, and the company states it has worked with many of the top global pharma and agrochemical companies.
Hypha's core technology platform is built around enzyme-based metabolite production. The PolyCYPs®+ kit combines 18 CYP isoforms with human aldehyde oxidase (AOX1) and FMO3, while the PolyUGTs kit covers 11 enzymes validated for O-, acyl-, and N-glucuronidation. These enzyme panels are complemented by chemical synthesis, microbial and mammalian biotransformation (S9 fractions and microsomes), late-stage functionalisation techniques (PolarExplorer, deoxyfluorination), and quantitative NMR spectroscopy for definitive structure elucidation. The integrated workflow enables production of difficult-to-synthesise metabolites at scale and supports regulatory-grade deliverables.
The commercial motion is direct B2B field sales into R&D departments of pharmaceutical and agrochemical enterprises, supported by content marketing (Metabolite Tales blog), quarterly newsletters, webinars, conference participation, publications, and case studies. Pricing is not publicly disclosed and is quote-based per project. The firm distributes globally from its UK base and sells screening kits directly via its website. Recent activity in 2026, including a quarterly newsletter cadence focused on LC-MS/MS MetID and PROTAC MetID, a Scientific Fellow hire, and active product launches, indicates ongoing reinvestment in both scientific depth and commercial reach.
Hypha Discovery firmographics
Firmographics- Name
- Hypha Discovery
- Legal name
- Hypha Discovery
- Website
- https://hyphadiscovery.co.uk
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Hypha Discovery is a UK-based specialist CRO that produces drug and pesticide metabolites and derivatives for global pharmaceutical and agrochemical companies, combining proprietary enzyme screening kits with biotransformation and NMR-based structure elucidation services.
- Ownership category
- akta.pro rank
Hypha Discovery industry classification
Industry- Product category
- Drug Metabolism Contract Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- DMPK / ADME & Bioanalysis (HLAGAFAC), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
Keywords
Where Hypha Discovery is headquartered
LocationHeadquarters
- HQ city
- Abingdon
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Hypha Discovery business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- MetID Services: End-to-end metabolite identification services supporting clients across drug discovery and development, from pinpointing metabolic soft spots in early-stage compounds to detailed biotransformation studies using LC-MS/MS and NMR spectroscopy.
- Metabolite Synthesis: Custom synthesis of CYP and non-CYP phase 1 metabolites, glucuronides and other conjugates, and mixed pathway metabolites using chemical synthesis, recombinant enzymes, microbial and mammalian biotransformation.
- Purification Services: Purification from complex matrices with purity assessments by UV/ELSD/NMR and Certificates of Analysis.
- Screening Kits (PolyCYPs, PolyUGTs): Sale of proprietary screening kit products for scientists to produce metabolites in their own laboratories. UDPGA co-factor included; fully scalable.
- Custom Natural Product Synthesis: Acquisition, storage and maintenance of strains; strain improvement and fermentation optimisation; purification and identification services.
- Contract Fermentation: Fermentation services for natural product and metabolite production.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels9 records
Hypha Discovery product offering
Product offeringCore offering
Hypha Discovery is a UK-based Contract Research Organization (CRO) that delivers custom metabolite synthesis, purification, and identification (MetID) services for pharmaceutical and agrochemical R&D clients. The company combines chemical synthesis, recombinant enzymes (including its proprietary PolyCYPs and PolyUGTs screening kits), and microbial/mammalian biotransformation to produce drug and pesticide metabolites, including difficult-to-synthesise CYP and non-CYP phase I metabolites, glucuronides, and conjugates, with structure elucidation by LC-MS/MS and quantitative NMR.
Product overview
Hypha Discovery operates as a specialist CRO (Contract Research Organization) offering a comprehensive suite of metabolite synthesis and identification services. The company's product portfolio includes PolyCYPs®+ Screening Kits for CYP-derived phase I metabolites, PolyUGTs Screening Kits for glucuronide production, Human Aldehyde Oxidase (AOX1), and Human FMOs. These products complement their service offerings which include MetID Services (LC-MS/MS and NMR-based metabolite identification), Metabolite Synthesis (CYP/non-CYP phase I, glucuronides, conjugates), Purification, Structure Elucidation and NMR, Late-Stage Functionalisation (PolarExplorer, Deoxyfluorination), Custom Natural Product Synthesis, Contract Fermentation, and Certificates of Analysis. The product kits enable scientists to produce metabolites in their own laboratories while the service offerings provide end-to-end expertise for pharmaceutical and agrochemical R&D.
Differentiator
Problem solved
Functional benefit
Brands
- PolyCYPs®+: Screening kits providing a quick and convenient way to access CYP-derived and other phase I metabolites. Kits comprise 18 PolyCYP isoforms together with human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3).
- PolyUGTs
- PolarExplorer
- Human Aldehyde Oxidase (AOX1)
- Human FMOs
Products and services
- PolyCYPs®+ Screening Kits Screening kits providing a quick and convenient way for scientists to access CYP-derived and other phase I metabolites. Kits comprise 18 PolyCYP isoforms together with human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3), and are scalable for metabolite production in customer laboratories.
- PolyUGTs Screening Kits Screening kits used to screen for and scale up production of glucuronides of drugs, agrochemicals and other small molecules. The 11 enzymes in the kit have been tested for biocatalytic activity including O-glucuronidation of alkyl and phenolic hydroxyls, acyl-glucuronidation of carboxylic acids, and N-glucuronidation of aromatic nitrogen-containing systems. UDPGA co-factor is included.
- PolyCYPs Kits for Late-Stage Oxidation Specialized PolyCYPs kits configured for late-stage oxidation reactions, enabling production of hydroxylated and other oxidised derivatives of lead compounds for medicinal chemistry applications.
- Human Aldehyde Oxidase (AOX1) Recombinant human aldehyde oxidase enzyme product for metabolite synthesis and biotransformation studies.
- Human FMOs Human flavin-containing monooxygenases including FMO3 and other isoforms sold as recombinant enzyme products for metabolite production.
- MetID (Metabolite Identification) Services End-to-end metabolite identification services supporting drug discovery and development, from pinpointing metabolic soft spots in early-stage compounds through detailed biotransformation studies using LC-MS/MS and NMR spectroscopy. Delivered to pharmaceutical and agrochemical R&D clients.
- Metabolite Synthesis Services Custom synthesis of CYP and non-CYP phase I metabolites, glucuronides and other conjugates, and mixed pathway metabolites using chemical synthesis, recombinant enzymes, microbial biotransformation, and mammalian biotransformation. Scalable synthesis of difficult-to-produce metabolites is a core capability.
- Metabolite Purification Services Purification of metabolites from complex matrices with purity assessments by UV/ELSD/NMR and issuance of Certificates of Analysis.
- Late-Stage Functionalisation Services (PolarExplorer and Deoxyfluorination) Late-stage functionalisation services including PolarExplorer (facile generation of hydroxylated compounds on complex molecular cores) and Deoxyfluorination (selective fluorination of organic compounds) for medicinal chemistry SAR expansion.
- Structure Elucidation / NMR Spectroscopy Services Definitive structure elucidation, interpretation and documentation of spectra using state-of-the-art NMR instrumentation including quantitative NMR for metabolite identification and regulatory-grade documentation.
- Custom Natural Product Synthesis Services Acquisition, storage and maintenance of microbial strains; strain improvement and fermentation optimisation; purification and identification services for natural products.
- Contract Fermentation Services Contract fermentation services for natural product and metabolite production using Hypha's maintained microbial strains and fermentation capabilities.
Quantifiable outcome
- Delivered 60mg of phase I metabolite and over 100mg of phase II metabolite at high purity for Incyte Corporation
Companies that use Hypha Discovery
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Hypha Discovery technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Hypha Discovery partnerships and signals
Strategic signalScale indicators1 record
Expansion highlights4 records
Hypha Discovery competitors and assessment
Company assessmentDirect peers
- Sekisui Xenotech: Specialist DMPK/metabolism CRO offering in vitro ADME and metabolite identification services and related reagent products. Direct competitor to Hypha in drug-metabolite production and characterization for pharma clients.
- BioIVT (BioreclamationIVT): Supplies biological specimens and offers metabolism/biotransformation research services to pharma. Comparable use cases in metabolite standards and drug-metabolism studies position it as a direct specialized peer.
- Absorption Systems (Eurofins Discovery): Preclinical CRO focused on drug absorption, metabolism, and pharmacokinetics including MetID. Acquired by Eurofins, it directly overlaps Hypha's MetID and biotransformation service portfolio.
- Inotiv: Preclinical CRO offering DMPK, metabolite identification and safety services. Operates as a mid-size services peer with comparable study types and customer base.
Broad incumbents
- Eurofins Discovery: Broad discovery CRO offering ADME/PK, metabolite identification, medicinal chemistry and in vitro pharmacology. Larger incumbent that competes for the same pharma and agrochem sponsor budgets.
- Charles River Laboratories: Large preclinical CRO offering DMPK, safety assessment, and discovery services. Competes with Hypha on metabolite identification and broader preclinical outsourcing packages.
- Pharmaron: Global CRO/CDMO with full-spectrum discovery, DMPK and manufacturing services. Overlaps Hypha's MetID, metabolite synthesis and agrochemical R&D support offerings.
- WuXi AppTec: Large contract discovery and development platform including in vitro ADME/DMPK and chemistry services. Represents a scaled incumbent in metabolite-related CRO work.
- Thermo Fisher Scientific (Patheon / PPD): Diversified life-sciences services giant offering drug discovery, DMPK and analytical services via Patheon/PPD. Broad incumbent that competes for enterprise preclinical outsourcing contracts.
Regional players
- Sai Life Sciences: India-based discovery and development CRO providing DMPK/ADME, custom synthesis and biotransformation services. Operates from a different geography than Hypha but competes for similar global outsourced DMPK programs.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Hypha Discovery social profiles
Digital presenceHypha Discovery financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hypha Discovery leadership team
Management profileNumber of profiles
Profiles4 records
Hypha Discovery funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hypha Discovery M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hypha Discovery
What does Hypha Discovery do?
Hypha Discovery is a UK-based Contract Research Organization (CRO) that delivers custom metabolite synthesis, purification, and identification (MetID) services for pharmaceutical and agrochemical R&D clients. The company combines chemical synthesis, recombinant enzymes (including its proprietary PolyCYPs and PolyUGTs screening kits), and microbial/mammalian biotransformation to produce drug and pesticide metabolites, including difficult-to-synthesise CYP and non-CYP phase I metabolites, glucuronides, and conjugates, with structure elucidation by LC-MS/MS and quantitative NMR.
Is Hypha Discovery a public or private company?
Hypha Discovery is a private company. It is classified as unknown and is currently operating.
When was Hypha Discovery founded?
Hypha Discovery was founded in 2004. It employs 11 to 50 people.
Where is Hypha Discovery based?
Hypha Discovery is headquartered in Abingdon, United Kingdom, in the Europe region.
How does Hypha Discovery make money?
Six revenue lines are on record. MetID Services are the primary driver. The others are metabolite Synthesis, purification Services, screening Kits (PolyCYPs, PolyUGTs), custom Natural Product Synthesis and contract Fermentation.
Who are Hypha Discovery's main competitors?
Direct peers on record are Sekisui Xenotech, BioIVT (BioreclamationIVT), Absorption Systems (Eurofins Discovery) and Inotiv. Broad incumbents are Eurofins Discovery, Charles River Laboratories, Pharmaron, WuXi AppTec and Thermo Fisher Scientific (Patheon / PPD). Sai Life Sciences is listed as a regional player.
Does Hypha Discovery have an API?
No public API is recorded for Hypha Discovery.
What industry is Hypha Discovery in?
Hypha Discovery's product category is Drug Metabolism Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 5417 and its SIC code is 8731.